Going from immutable to mutable atherosclerotic plaques

American Journal of Cardiology

Volumn 88, Issue 4 SUPPL. 1, 2001, Pages 2-9

  Davies, Michael J ^a,b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART FAILURE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; DRUG MECHANISM; HEART DISEASE; HIGH RISK POPULATION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

EID: 0035899444     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01870-7     Document Type: Article

References (69)

1. Morphological characteristics of clinically significant coronary artery stenosis in stable angina
2. Morphometric analysis of the composition of atherosclerotic plaques in the four major epicardial coronary arteries in acute myocardial infarction and in sudden coronary death
3. Coronary risk factors and plaque morphology in men with coronary heart disease who died suddenly
4. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
5. Molecular bases of the acute coronary syndromes
6. Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity
7. -/- mice reveals a role for chemokines in the initiation of atherosclerosis
8. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries
9. Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase
10. Stability and instability: Two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995
11. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content
12. Coronary plaque disruption
13. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
14. Coronary plaque erosion without rupture into a lipid core: A frequent cause of coronary thrombosis in sudden coronary death
15. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques
16. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction
17. The composition of coronary-artery plaques
18. Coronary angiography morphology in acute myocardial infarction: Link between the pathogenesis of unstable angina and myocardial infarction
19. Coronary thrombi increase PTCA risk: Angioscopy as a clinical tool
20. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death
21. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death
22. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes
23. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection
24. Pathological concepts in acute coronary thrombosis: Relevance to treatment
25. Angiographic stenosis progression and coronary events in patients with "stabilized" unstable angina
26. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death
27. Chronic ulcerated plaques: New insights into the pathogenesis of acute coronary disease
28. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men
29. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
30. Atherogenic diets enhance endotoxin-stimulated interleukin-1 and tumor necrosis factor gene expression in rabbit aortae
31. Mechanisms of progression in native coronary artery disease: Role of healed plaque disruption
32. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
33. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
34. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
35. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
36. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial
37. Animal models of atherosclerosis
38. Effects of low-dose pravastatin sodium on plasma cholesterol levels and aortic atherosclerosis of heterozygous WHHL rabbits fed a low cholesterol (0.03%) enriched diet for one year
39. Plaque changes and arterial enlargement in atherosclerotic monkeys after manipulation of diet and social environment
40. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits
41. The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypercholesterolemic therapy on coronary atherosclerosis in angiographic trials
42. Low-density lipoprotein independent effects of statins
43. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS)
44. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: A randomized, placebo-controlled, double-blind study
45. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
46. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
47. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
48. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL
49. Simvastatin decreases aldehyde production derived from lipoprotein oxidation
50. Direct vascular effects of HMG-CoA reductase inhibitors
51. Lovastatin mediated G1 arrest is through inhibition of the proteasome independent of hydroxymethyl glutaryl-CoA reductase
52. Direct effects of statins on the vascular wall
53. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies
54. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells
55. Vastatins inhibit tissue factor in cultured human macrophages
56. Hyperlipidemia and coronary disease: Correction of the increased thrombogen potential with cholesterol reduction
57. Randomised placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids
58. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization
59. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
60. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: A study in an atherosclerotic hypercholesterolemic rabbit
61. Progression of coronary artery disease predicts clinical coronary events: Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study
62. Plaque stabilization: A mechanism for the beneficial effect of lipid-lowering therapies in angiographic studies
63. Modification of coronary artery disease progression by cholesterol-lowering therapy: The angiographic studies
64. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction
65. Effects of atorvastatin on early recurrent ischemic events in patients with acute coronary syndromes: The MIRACL Study - A randomized controlled trial
66. Mutations in the low-density lipoprotein receptor gene in Swedish familial hypercholesterolaemia patients: Clinical expression and treatment response
67. Chronic infections and coronary heart disease: Is there a link?
68. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-α and matrix metalloproteinase expression
69. Kinetics of calcium and calmodulin-dependent protein kinase III from embryonic chicken leg muscle cells